Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study

Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study

IntroductionThe relationship between immune-related thyroid dysfunction (irTD) and survival rates in cancer patients remains unclear. Furthermore, the impact of variations in immunotherapy line numbers and pathological types among lung cancer patients on this relationship has not been fully elucidat...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ge Guo, Zihan Jing, Wenrui Dou, Guiqin Wang, JunJie Dang, Yajie Li, Ruqiong Wang, Huan Zhang, Jing Sun, Lihua Shang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	lung neoplasms immune checkpoint inhibitor irAEs immune-related thyroid dysfunction prediction biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495460/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
by: Le Xu, et al.
Published: (2025-12-01)

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
by: Chen Li, et al.
Published: (2025-05-01)

Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events
by: Khashayar Esfahani, et al.
Published: (2025-02-01)

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade
by: Nina B. Curkovic, et al.
Published: (2025-12-01)

Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review
by: Xiaolin Zhao, et al.
Published: (2025-02-01)

Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors
by: Ping Luo, et al.
Published: (2025-12-01)

Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)
by: Clémence M. C. Huigen, et al.
Published: (2025-08-01)

Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
by: Harun Muğlu, et al.
Published: (2025-02-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment
by: John Storwick, et al.
Published: (2025-07-01)

The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
by: Tianhang Zhang, et al.
Published: (2024-12-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature
by: Jiaxiang Ji, et al.
Published: (2024-12-01)

Immune Checkpoint Inhibitor-Related Sjögren’s Syndrome: An Ocular Immune-Related Adverse Event
by: Hideki Fukuoka, et al.
Published: (2025-05-01)

Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy
by: Caroline J. Cushman, et al.
Published: (2024-11-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
by: Qing Zhang, et al.
Published: (2025-04-01)

A Case of Hemophagocytic Lymphohistiocytosis During Immune Checkpoint Inhibitor Treatment for Metastatic Renal Cell Carcinoma, Complicated by Pancytopenia Attributed to Cytomegalovirus Infection
by: Tomoko Honda, et al.
Published: (2025-07-01)

Multidisciplinary intervention for adverse events associated with ATZ + BEV therapy: a case report
by: Ko Masaki, et al.
Published: (2025-05-01)

Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
by: Shuxian Pan, et al.
Published: (2025-01-01)

Case Report: Laser speckle flowgraphy in a patient with uveitis due to immune-related adverse events by immune checkpoint inhibitors
by: Satoru Kase, et al.
Published: (2025-05-01)

Molecular analysis of immune checkpoint inhibitor associated erythema nodosum-like toxicity
by: Xiaopeng Sun, et al.
Published: (2025-03-01)

Peripheral blood markers predict prognosis and irAEs of stage IV driver gene-negative lung adenocarcinoma treated with ICIs
by: Yu Li, et al.
Published: (2025-03-01)

Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction
by: Yanyan Jiao, et al.
Published: (2025-08-01)

Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
by: Mengyuan Liu, et al.
Published: (2025-03-01)

Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
by: Mengyuan Liu, et al.
Published: (2025-05-01)

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis
by: Xiaomin Fu, et al.
Published: (2025-05-01)

Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study
by: Isabel Manger, et al.
Published: (2025-03-01)

Editorial for “a predictive model for irAEs in ESCC patients treated with PD-1 inhibitors based on blood indicators”
by: Yaser Soleimani, et al.
Published: (2025-12-01)

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Late-onset bone granulomatous reaction of hand from immune checkpoint-inhibitors detected on FDG-PET/CT
by: Miki Nishimori, et al.
Published: (2025-05-01)

Mechanisms of autoimmune-mediated paraneoplastic syndromes: immune tolerance and disease pathogenesis
by: César Pérez-Bucio, et al.
Published: (2025-05-01)

Risk factors and outcomes of thyroid immune-related adverse events following PD-1/PD-L1 inhibitors treatment in a large tertiary Chinese center
by: Wenwen Gong, et al.
Published: (2025-07-01)

Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma?
by: Sophia Wasserer, et al.
Published: (2025-03-01)

Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
by: Xueqian Mao, et al.
Published: (2025-06-01)

Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland
by: Renata Pacholczak-Madej, et al.
Published: (2025-06-01)

Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis
by: Jennifer Strouse, et al.
Published: (2024-12-01)

Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
by: Klajdi Begaj, et al.
Published: (2025-06-01)

Prevention and management of immune-related adverse events for biliary tract cancers
by: LIU Kun, GUO Wei
Published: (2025-03-01)

Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes
by: Hui Yang, et al.
Published: (2025-05-01)